阿昔单抗 T76844

Product Introduction
Bioactivity


英文名: Abciximab

描述: Abciximab (C7E3) 是一种小鼠/人嵌合单克隆抗体，是一种有效的糖蛋白 IIb/IIIa (glycoprotein IIb/IIIa) 抑制剂。 Abciximab 具有抗血小板聚集和白细胞粘附的作用，通过与糖蛋白 IIb/IIIa、vitronectin 和 Mac-1 受体结合发挥作用。

体外活性: Inhibiting platelet aggregation induced by physiologic and pathologic agonists, abciximab (C7E3) achieves this effect by binding to the platelet αIIbβ3 integrin[2].Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2].

体内活性: Effectively preventing neointimal hyperplasia, abciximab (C7E3) is administered at a dose of 0.25 mg/kg/day via intravenous infusion for 28 days[2].

存储条件: store at low temperaturestore at -20°C

关键字: Abciximab

相关产品: Cyclo(-RGDfK) TFA | Firategrast | Vedolizumab | Synstatin (92-119) | BT100 | Vaccarin | Cyclo(RGDyK) | Bimosiamose | Natalizumab | Elarofiban

阿昔单抗 T76844信息由TargetMol中国为您提供，如您想了解更多关于阿昔单抗 T76844报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途